Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation

Keyphrases

• Epstein-Barr Virus 100%
• Post-transplant Lymphoproliferative Disorder 100%
• Hematopoietic Stem Cell Transplantation 100%
• B Cells 50%
• Virus Load 50%
• Quantitative PCR 25%
• Clinical High Risk 25%
• T Cells 25%
• Monoclonal Antibody 25%
• Blood Samples 25%
• Peripheral Blood 25%
• Major Risk Factors 25%
• Pretransplant 25%
• Marrow 25%
• T Cell Depletion 25%
• Cytotoxic T Cells 25%
• Virus-specific 25%
• Reaction-based 25%
• Antithymocyte Globulin 25%
• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) 25%
• Graft-versus-host Disease (GvHD) 25%
• Mismatched Related Donor 25%
• Early Development 25%
• HLA Matching 25%
• Therapy Initiation 25%
• Donor-derived 25%
• Early Initiation 25%
• Preemptive Treatment 25%
• Remaining Challenges 25%
• Precise Measurement 25%
• Anti-B 25%

Medicine and Dentistry

• Epstein Barr Virus 100%
• Lymphoproliferative Disease 100%
• Hematopoietic Stem Cell Transplantation 100%
• B Cell 50%
• In Vitro 25%
• Real-Time Polymerase Chain Reaction 25%
• T Cell 25%
• Monoclonal Antibody 25%
• Cytotoxic T-Cell 25%
• Thymocyte Antibody 25%
• Acute Graft Versus Host Disease 25%
• Allogeneic Hematopoietic Stem Cell Transplantation 25%
• T Lymphocyte Antibody 25%

Immunology and Microbiology

• Epstein Barr Virus 100%
• Hematopoietic Stem Cell Transplantation 100%
• B Cell 50%
• Viral Load 50%
• Real-Time Polymerase Chain Reaction 25%
• Monoclonal Antibody 25%
• Cytotoxic T Cell 25%
• T Cell Depletion 25%
• Anti-Thymocyte Globulin 25%
• Acute Graft Versus Host Disease 25%
• Allogeneic Hematopoietic Stem Cell Transplantation 25%
• T Lymphocyte Antibody 25%
• In Vitro 25%